Therefore, genetic or pharmacological modulation of IGF-1/PI3K/CREB/CA12 activity may be a promising therapeutic approach to degenerative disc disease and a novel model for research focusing on IVDD and endplate degeneration. This evidence concerns the gene CREB1 and intervertebral disk degenerative disorder.